Can the NHS become a world-class healthcare system?
October 25, 2005Sales and Marketing
Tony Blair and Labour were re-elected in May this year for an historic third-term, with the electorate telling pollsters they …
Oxford BioMedica’s lung cancer candidate shows promise
October 25, 2005Research and Development
A promising antibody developed by UK-based Oxford BioMedica is poised to enter clinical trials to treat lung cancer.The 5T4 antibody-targeted …
Pharma continues to invest in UK research and development
October 24, 2005Sales and Marketing Pfizer, R&D
UK pharma and biotech companies increased R&D investment by 4% in the last year, according to the latest government figures.The …
Blockbuster partnerships
October 21, 2005Research and Development
Since pharma'ps big wave of innovation during the early 1990s, peaking in 1996 when 131 new drug applications were filed …
Vaccine companies to compete for UK pandemic contract
October 20, 2005Sales and Marketing
Vaccine companies are to compete with each other to produce a vaccine against a potential pandemic flu – although no-one …
New approvals in TNF-blocker class
October 20, 2005Sales and Marketing
Competition in one of the industry's fastest growing markets is intensifying with new approvals for two TNF-blocker drugs.Schering-Plough and Centocor's …
Resolute wins PR Consultancy of the Year award
October 20, 2005Medical Communications
Healthcare agency Resolute Communications has been named consultancy of the year at the PRWeek awards, believed to be the first …
Once a day pill promises period-free contraception
October 20, 2005Sales and Marketing
The world's first-ever contraceptive pill to offer women complete freedom from menstruation could be launched by next year.Wyeth's Lybrel is …
Tarceva/Avastin combination disappoints in kidney cancer
October 19, 2005Sales and Marketing
Early results from trials suggest adding Tarceva to Avastin has no extra benefit in the treatment of kidney cancer.Researchers at …
Pharma – partners of NHS choice?
October 19, 2005The government sees choice as a major driver for promoting quality, responsiveness, efficiency and equity in public services. Choice in …
Merck to co-develop novel prostate cancer candidate
October 18, 2005Research and Development
Merck is to develop a new monoclonal antibody which has shown promise in treating prostate cancer.The US company has signed …
Exubera recommended by European regulator
October 18, 2005Sales and Marketing
Exubera, the first ever inhaled insulin product is set for approval in Europe following a key regulatory recommendation.The positive opinion …
Winning CROs look east for expansion
October 18, 2005Research and Development
The new onus on outsourcing has seen CROs reap the benefits of an industry striving to cut resource investment while …
Pharma increases vaccine production as bird flu hits Europe
October 14, 2005Manufacturing and Production
Pharmaceutical companies are being urged to step up vaccine production as the strain of bird flu that killed 59 people …
Pfizer wins UK Lipitor court battle
October 14, 2005Sales and Marketing
Pfizer has won an important legal battle to maintain its UK patent on best-selling cholesterol drug Lipitor.The UK High Court …
Sanofi-Aventis launch new short-acting insulin competitor Apidra
October 13, 2005Sales and Marketing
Apidra, a new short-acting insulin analogue, has been launched in the UK by Sanofi-Aventis.Short-acting analogues have a faster onset of …
EMEA reforms to speed drug approval
October 13, 2005Sales and Marketing
Europe's medicines regulator is looking to communicate more effectively with pharma companies as part of a drive to accelerate drug …
Merck looks to rebuild reputation one year on from Vioxx
October 13, 2005Sales and Marketing
Merck looks set to launch a new public relations campaign across Europe in an attempt to repair damage done to …
Unions vote against NHS ‘privatisation’
October 13, 2005The government lost the vote at its party conference on expanding the role of the private sector in the NHS.A …
VNU shareholders rebel over IMS bid
October 13, 2005Sales and Marketing
A significant minority of shareholders in VNU are against its planned $7 billion acquisition of pharmaceutical information company IMS Health.The …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
